SPEER-4C Inhibitors
SPEER-4C inhibitors encompass a diverse array of chemical compounds that target various signaling pathways and biological processes to ultimately decrease the functional activity of SPEER-4C. For instance, Erlotinib and LY294002, both act upon the PI3K/AKT signaling pathway; while Erlotinib targets the EGFR tyrosine kinase to reduce activation of this pathway, LY294002 directly inhibits PI3K, thereby potentially diminishing SPEER-4C function if it is related to this pathway. Similarly, Rapamycin and Palbociclib disrupt the mTOR pathway and cell cycle progression respectively, which could lead to the suppression of SPEER-4C if it is involved in these processes. U0126, PD98059, and Sorafenib all target the MAPK/ERK pathway at different junctures – U0126 and PD98059 inhibit MEK1/2, whereas Sorafenib inhibits multiple kinases including RAF, MEK, and ERK, which might lead to indirect inhibitionof SPEER-4C if it is regulated by this pathway. Dasatinib, with its broad kinase inhibition spectrum, could deter multiple signaling pathways that may affect SPEER-4C activity, and SB431542 specifically targets the TGF-β receptor type I, potentially influencing SPEER-4C if it acts downstream. Bortezomib's role in inhibiting proteasomal degradation could alter the turnover of regulatory proteins involved in SPEER-4C's functional pathway.
Moreover, Sorafenib's multi-kinase inhibition can extend to pathways in which SPEER-4C may be involved, thereby reducing its activity. WZ4003, by inhibiting NUAK kinases, could indirectly affect SPEER-4C if it is implicated in cellular stress responses. SP600125's inhibition of JNK signaling could lead to a decrease in SPEER-4C function if it is associated with apoptosis or cell differentiation pathways. These inhibitors, despite their diverse targets, align in their collective potential to attenuate SPEER-4C activity by modulating the activity of signaling pathways that SPEER-4C may be connected to or regulated by, thus demonstrating the intricate network of cellular signaling and its impact on protein function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Inhibition of EGFR can downregulate the PI3K/AKT signaling pathway, which might be indirectly involved in regulating SPEER-4C expression or activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, and mTOR is a central regulator of cell growth and proliferation. By inhibiting mTOR, rapamycin could suppress the translation of proteins involved in the mTOR pathway, potentially affecting SPEER-4C function if it is linked to this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which prevents the activation of the MAPK/ERK pathway. If SPEER-4C is regulated by or associated with the MAPK/ERK pathway, U0126 would indirectly inhibit its function by blocking this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can attenuate the PI3K/AKT/mTOR signaling pathway. If SPEER-4C is indirectly affected by this pathway, its functional activity could be reduced by LY294002. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. It can interfere with multiple signaling pathways, including those regulating cell proliferation and survival. SPEER-4C activity could be indirectly inhibited if it interacts with these pathways. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β receptor type I. It can disrupt the TGF-β signaling pathway, which could lead to indirect inhibition of SPEER-4C if it is a downstream effector of this pathway. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, which are pivotal in cell cycle progression. Inhibition of these kinases could indirectly affect SPEER-4C if it is involved in cell cycle regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can disrupt multiple cellular signaling pathways by preventing the degradation of regulatory proteins. SPEER-4C function could be diminished if it relies on proteasome-mediated regulatory mechanisms. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multikinase inhibitor that can affect several signaling pathways, including RAF/MEK/ERK. If SPEER-4C is modulated by any of these pathways, sorafenib could lead to its functional inhibition. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective inhibitor of the NUAK family kinase 1 and 2, which are involved in regulating cellular stress responses. If SPEER-4C is implicated in stress response pathways, WZ4003 could indirectly inhibit its function. | ||||||